PDL BioPharma, Inc. Current Ratio

Current Ratio of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Ratio growth rates and interactive chart. The current ratio is a liquidity ratio that measures whether a firm has enough resources to meet its short-term obligations. It is calculated as current assets divided by current liabilities. A ratio below 1 indicates potential trouble for a company, as it doesn't have enough current assets to pay for its short-term liabilities. A ratio above 2 is usually considered healthy.


Highlights and Quick Summary

  • Current Ratio for the quarter ending June 29, 2020 was 13.68 (a 3.56% increase compared to previous quarter)
  • Year-over-year quarterly Current Ratio increased by 37.56%
  • Annual Current Ratio for 2019 was 6.87 (a -30.31% decrease from previous year)
  • Annual Current Ratio for 2018 was 9.86 (a 197.22% increase from previous year)
  • Annual Current Ratio for 2017 was 3.32 (a 8.58% increase from previous year)
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Ratio of PDL BioPharma, Inc.

Most recent Current Ratioof PDLI including historical data for past 10 years.

Interactive Chart of Current Ratio of PDL BioPharma, Inc.

PDL BioPharma, Inc. Current Ratio for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 13.68 13.21
2019 6.87 9.94 10.43 11.02 6.87
2018 9.86 10.88 11.13 10.03 9.86
2017 3.32 3.16 1.94 1.98 3.32
2016 3.05 2.92 14.19 13.04 3.05
2015 7.69 3.24 2.55 1.46 7.69
2014 1.89 1.31 0.75 1.03 1.89
2013 0.26 1.59 1.2 3.76 0.26
2012 17.47 6.28 2.56 1.38 17.47
2011 1.76 1.26 0.98 0.53 1.76
2010 1.47 1.12 0.78 1.47

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.